Chargement en cours...
Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease
BACKGROUND AND OBJECTIVES: In the 3-year Tolvaptan Efficacy and Safety in Management of ADPKD and Its Outcomes (TEMPO) 3:4 and 1-year Replicating Evidence of Preserved Renal Function: an Investigation of Tolvaptan Safety and Efficacy in ADPKD (REPRISE) trials, tolvaptan slowed the decline of eGFR in...
Enregistré dans:
| Publié dans: | Clin J Am Soc Nephrol |
|---|---|
| Auteurs principaux: | , , , , , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
American Society of Nephrology
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6086720/ https://ncbi.nlm.nih.gov/pubmed/30026287 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.01520218 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|